Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging agent could sharpen cancer detection

NCT ID NCT06977945

Recruiting now Diagnosis Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new imaging agent called FL-091, which targets a protein (NTSR1) found on some cancer cells. Researchers will use it with PET or SPECT scans to see if it can better detect and stage cancers like head and neck, colorectal, and pancreatic cancer. About 100 adults with suspected or confirmed NTSR1-positive tumors will take part. The goal is to see how well the agent highlights tumors and where it goes in the body, laying groundwork for future targeted treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FL-091 (a radionuclide imaging agent)
What this could lead to
If successful, this could lead to a more accurate way to detect and stage certain cancers, potentially guiding better treatment decisions.
What could go wrong
This is an early diagnostic study with only 100 participants, so results may not apply to all patients. The imaging agent's effectiveness and safety are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer head and neck cancer pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT TUMORS WITH POSITIVE NTSR1 EXPRESSION

Contacts and locations

Locations

  • Wuhan Union Hospital,China

    RECRUITING

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.